6919 — CALIWAY BIOPHARMACEUTICALS Share Price
Last trade - 00:00- TWD99.60bn
- TWD95.66bn
- TWD38.04m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 13 | ||
| PEG Ratio (f) | 0.22 | ||
| EPS Growth (f) | 149.09% | ||
| Dividend Yield (f) | 2.31% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 10.82 | ||
| Price to Tang. Book | 10.82 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3,388.67 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.88% | ||
| Return on Equity | -2.77% | ||
| Operating Margin | -2827.47% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 12.34 | 12.82 | 38.93 | 44.43 | 38.04 | 6,032 | 11,732 | 29.73% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +127.54 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Caliway Biopharmaceuticals Co Ltd is a Taiwan-based company primarily engaged in the development of new drugs for medical aesthetics, chronic inflammatory diseases, and aging. The Company's products include CBL-514, mainly used for non-surgical localized fat reduction and improvement of cellulite; CBL-514D, mainly used to treat Sclerosis and sleep apnea; CBA-539, mainly used for pigmentation, skin whitening, and anti-aging; and CBF-520, mainly used to treat central obesity. The Company sells its products in domestic and international markets, with the United States, Canada, China, and Europe as the primary regions.
Directors
- Lu-Hui Hsu CHM
- Yu-Fang Ling CEO
- Chuan-Cheng Chiu DRC
- Kao-Jung Chang DRC
- Hsien-Li Peng IND
- Yen-Miao Chen OTH
- Hui-Min Chang OTH
- Ching-Po Lin IND
- Pao-Chu Luo IND
- Lu-Chi Chung DGM
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- October 22nd, 2012
- Public Since
- December 26th, 2022
- No. of Shareholders
- 66,007
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 1,556,299,860
- Address
- 32F-9, No.99, Section 1,, NEW TAIPEI CITY, 221
- Web
- https://www.caliwaybiopharma.com/
- Phone
- +886 226971355
- Contact
- Hui-Min Chang
- Auditors
- KPMG LLP
Latest News for 6919
Upcoming Events for 6919
Q3 2026 CALIWAY BIOPHARMACEUTICALS CO., LTD. Earnings Release
Q4 2026 CALIWAY BIOPHARMACEUTICALS CO., LTD. Earnings Release
Q1 2027 CALIWAY BIOPHARMACEUTICALS CO., LTD. Earnings Release
Similar to 6919
Adimmune
Taiwan Stock Exchange
BORA PHARMACEUTICALS
Taiwan Stock Exchange
BRIM BIOTECHNOLOGY
Taiwan Stock Exchange
Cenra
Taiwan Stock Exchange
Chunghwa Chemical Synthesis & Biotech
Taiwan Stock Exchange
FAQ
As of Today at 18:45 UTC, shares in CALIWAY BIOPHARMACEUTICALS are trading at TWD64.00. This share price information is delayed by 15 minutes.
Shares in CALIWAY BIOPHARMACEUTICALS last closed at TWD64.00 and the price had moved by -56.16% over the past 365 days. In terms of relative price strength the CALIWAY BIOPHARMACEUTICALS share price has underperformed the FTSE Developed Asia Pacific Index by -66.77% over the past year.
The overall consensus recommendation for CALIWAY BIOPHARMACEUTICALS is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCALIWAY BIOPHARMACEUTICALS does not currently pay a dividend.
CALIWAY BIOPHARMACEUTICALS does not currently pay a dividend.
CALIWAY BIOPHARMACEUTICALS does not currently pay a dividend.
To buy shares in CALIWAY BIOPHARMACEUTICALS you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD64.00, shares in CALIWAY BIOPHARMACEUTICALS had a market capitalisation of TWD99.60bn.
Here are the trading details for CALIWAY BIOPHARMACEUTICALS:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6919
Based on an overall assessment of its quality, value and momentum CALIWAY BIOPHARMACEUTICALS is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CALIWAY BIOPHARMACEUTICALS is TWD245.00. That is 282.81% above the last closing price of TWD64.00.
Analysts covering CALIWAY BIOPHARMACEUTICALS currently have a consensus Earnings Per Share (EPS) forecast of TWD2.36 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CALIWAY BIOPHARMACEUTICALS. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -31.32%.
As of the last closing price of TWD64.00, shares in CALIWAY BIOPHARMACEUTICALS were trading -40.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CALIWAY BIOPHARMACEUTICALS PE ratio based on its reported earnings over the past 12 months is 13. The shares last closed at TWD64.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CALIWAY BIOPHARMACEUTICALS' management team is headed by:
- Lu-Hui Hsu - CHM
- Yu-Fang Ling - CEO
- Chuan-Cheng Chiu - DRC
- Kao-Jung Chang - DRC
- Hsien-Li Peng - IND
- Yen-Miao Chen - OTH
- Hui-Min Chang - OTH
- Ching-Po Lin - IND
- Pao-Chu Luo - IND
- Lu-Chi Chung - DGM